Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy.

  • Verdonschot, Job A J
  • Fuster, Jose J
  • Walsh, Kenneth
  • Heymans, Stephane R B
The increased sensitivity of novel DNA sequencing techniques has made it possible to identify somatic mutations in small circulating clones of haematopoietic stem cells. When the mutation affects a 'driver' gene, the mutant clone gains a competitive advantage and has the potential to expand over time, a phenomenon referred to as clonal haematopoiesis (CH), which is emerging as a new risk factor for various non-haematological conditions, most notably cardiovascular disease (e.g. heart failure). Dilated cardiomyopathy (DCM) is a form of non-ischaemic heart failure that is characterized by a heterogeneous aetiology. The first evidence is arising that CH plays an important role in the disease course in patients with DCM, and a strong association of CH with multiple aetiologies of DCM has been described (e.g. inflammation, chemotherapy, and atrial fibrillation). The myocardial inflammation induced by CH may be an important trigger for DCM development for an already susceptible heart, e.g. in the presence of genetic variants, environmental triggers, and comorbidities. Studies investigating the role of CH in the pathogenesis of DCM are expected to increase rapidly. To move the field forward, it will be important to report the methodology and results in a standardized manner, so results can be combined and compared. The accurate measurement of CH in patients with DCM can provide guidance of specific (anti-inflammatory) therapies, as mutations in the CH driver genes prime the inflammasome pathway.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Circulating non-coding RNAs as biomarkers to predict and monitor the response to exercise: chances and hurdles

  • Gonzalo-Calvo, David de
  • Thum, Thomas
We have read the comment by Schmitz and Brand with great interest. We believe that several questions should be answered before accepting non-coding RNAs (ncRNAs) as functional markers in the context of exercise. Contrary to what happens with other cardiovascular therapies,1 the potential of ncRNAs to predict the response to acute exercise and/or training programs remains to be addressed. Previous studies demonstrated that circulating microRNAs (miRNAs) correlate with aerobic performance parameters such as VO2max.2 Specific circulating miRNA profiles have been observed in individuals with different cardiorespiratory fitness levels.3 Therefore, circulating ncRNAs could be useful to monitor cardiovascular health. Nonetheless, whether the baseline ncRNA signature reflects the molecular configuration required for any exercise protocol to exert a preventive and/or therapeutic effect in healthy subjects or cardiovascular patients is unknown. Furthermore, the results in the field of circulating miRNAs and exercise are heterogeneous and hardly comparable due to differences in the experimental designs, characteristics of the participants, and technical approaches.4 Additionally, the translation of ncRNAs to clinical practice is controversial due to relevant methodological limitations.1 This situation might not be linked to the poor performance of ncRNAs as biomarkers but additional efforts are needed, especially in terms of reproducibility., Juan de la Cierva-Incorporacio´n grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393 to D.d.G.-C.); CIBER Cardiovascular (CB16/11/00403 to D.d.G.-C.) is a project of the Instituto de Salud Carlos III; The EU, project HOMAGE, the ERANET-CVD LIPCAR-HF and the DFG (KFO311) to T.T, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction: A cardiovascular magnetic resonance study

  • Gonzalo-Calvo, David de
  • Cediel, Germán
  • Bär, Christian
  • Núñez,Julio
  • Revuelta-López, Elena
  • Gavara, Josep
  • Ríos-Navarro, César
  • Llorente-Cortés, Vicenta
  • Bodí, Vicente
  • Thum, Thomas
  • Bayés Genís, Antoni
Reliable noninvasive prognostic biomarkers for left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) are needed. This study aimed to evaluate a panel of circulating microRNAs (miRNAs) as biomarkers of LV remodeling using cardiovascular magnetic resonance (CMR). We prospectively evaluated patients with a first STEMI treated with primary percutaneous coronary intervention who underwent CMR imaging at 1 week and 6 months after STEMI (n = 70). miRNAs were measured using PCR-based technologies in plasma samples collected at admission. The associations between miRNAs and LV diastolic and systolic volumes, and ejection fraction at 6-months were estimated in adjusted models. Median age was 60 years, 71.4% were male. miR-1254 was significantly associated in univariate analyses. Patients in the highest tertile of miR-1254 exhibited lower values of LVEDVI and LVESVI and higher values of LVEF at 1 week. After comprehensive multivariate adjustment including clinical, CMR variables, hs-troponin-T and NT-proBNP, miRNA-1254 was associated with decreasing LVESVI (P = 0.006), and borderline negative associated with LVEDVI (P = 0.063) at 6-months. miR-1254 also exhibited a significant positive association with increasing LVEF during follow-up (P < 0.001). Plasma miRNA-1254 predicted changes in LV volumes and LVEF at 6 months after STEMI. The value of miR-1254 to inform tailored treatment selection and monitor ongoing efficacy deserves further investigation., DdG-C and VLl-C are members of the CardiolincTM network. DdG-C was a recipient of Juan de la CiervaIncorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393). CIBER Cardiovascular is a project of the Instituto de Salud Carlos III. VB was funded by the Instituto de Salud Carlos III and co-funded by FEDER (grant numbers PI17/01836 and PIE15/00013). TT was funded by the EU, project HOMAGE,the ERANET-CVD LIPCAR-HF and by Deutsche Forschungsgemeinschaf (DFG, KFO311). CB received support through Deutsche Forschungsgemeinschaf (BA5631/2-1)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction, A cardiovascular magnetic resonance study

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Cediel, Germán|||0000-0001-9667-7507
  • Bär, Christian
  • Núñez, Julio|||0000-0003-1672-7119
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Ríos-Navarro, César
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Bodi, Vicente|||0000-0001-6425-5828
  • Thum, Thomas|||0000-0003-4360-1511
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Reliable noninvasive prognostic biomarkers for left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) are needed. This study aimed to evaluate a panel of circulating microRNAs (miRNAs) as biomarkers of LV remodeling using cardiovascular magnetic resonance (CMR). We prospectively evaluated patients with a first STEMI treated with primary percutaneous coronary intervention who underwent CMR imaging at 1 week and 6 months after STEMI (n = 70). miRNAs were measured using PCR-based technologies in plasma samples collected at admission. The associations between miRNAs and LV diastolic and systolic volumes, and ejection fraction at 6-months were estimated in adjusted models. Median age was 60 years, 71.4% were male. miR-1254 was significantly associated in univariate analyses. Patients in the highest tertile of miR-1254 exhibited lower values of LVEDVI and LVESVI and higher values of LVEF at 1 week. After comprehensive multivariate adjustment including clinical, CMR variables, hs-troponin-T and NT-proBNP, miRNA-1254 was associated with decreasing LVESVI (P = 0.006), and borderline negative associated with LVEDVI (P = 0.063) at 6-months. miR-1254 also exhibited a significant positive association with increasing LVEF during follow-up (P < 0.001). Plasma miRNA-1254 predicted changes in LV volumes and LVEF at 6 months after STEMI. The value of miR-1254 to inform tailored treatment selection and monitor ongoing efficacy deserves further investigation.